Press Releases April 30, 2026 08:00 AM

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Lexicon Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call for May 7, 2026

By Ajmal Hussain LXRX
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company focused on pioneering medicines for neuropathic pain, cardiometabolic diseases, and obesity, announced it will report its first quarter 2026 financial results on May 7, 2026, prior to market open. The company will also host a conference call and webcast to discuss the results and provide a business update.

Key Points

  • Lexicon will release Q1 2026 financial results before market open on May 7, 2026.
  • A management conference call and webcast will be held to discuss the earnings and company updates.
  • The company has an active pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.
  • The announcement highlights Lexicon's ongoing development in the biopharmaceutical sector, particularly in cardiometabolic and metabolic disease areas.

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on the Lexicon website.  

About Lexicon Pharmaceuticals  
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Investor and Media Inquiries:  
Lisa DeFrancesco   
Lexicon Pharmaceuticals, Inc.  
[email protected]  


Risks

  • Financial results may fall short of market expectations, impacting stock price.
  • Pipeline drug candidates are in various stages of development, which carries inherent clinical and regulatory risks.
  • Market sentiment may remain cautious awaiting detailed financial and operational updates following the release.

More from Press Releases

Figure Technology Solutions Reports April 2026 Operating Data May 4, 2026 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 4, 2026 TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth May 4, 2026 Pennant Announces First Quarter 2026 Earnings Release and Call May 4, 2026 Magna Announces 2026 Annual Meeting Results May 4, 2026